Atlas Genetics Aims to Market POC MDx Platform, First Test for Chlamydia, by End of 2014 | GenomeWeb

Atlas Genetics, a UK-based firm specializing in point-of-care in vitro diagnostics, is aiming to market its first products — a low-cost, ultra-rapid, cartridge-based testing system and associated nucleic acid test for Chlamydia trachomatis — with CE marking by the end of 2014, a company representative said recently.

Soon thereafter, Atlas aims to then commercialize a combined chlamydia/gonorrhea molecular assay both in Europe and the US, followed by tests for Trichomonas vaginalis, herpes simplex virus, syphilis, and HIV.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.